Optos launches Monaco

Optos announces new product launch as they release their latest widefield device, Monaco to the European ophthalmic market. Monaco is a retinal imaging system with integrated OCT that produces a 200 degrees single capture optomap image in less than half a second and provides cross-sectional OCT views of retinal structures. It allows a multi-modality capture including colour and autofluorescence for both eyes in 90 seconds....

Omega receives first order under agreement

Alva-based life sciences firm extends their allergy testing portfolio to a menu of 58 different tests. The medical diagnostics company has secured its first order under a global distribution deal. The firm announced a tie-up with Immunodiagnostic Systems (IDS) earlier this year to launch products into the market. n a stock market announcement the firm said that commercialisation activities with IDS are proceeding to plan...

Scotland does indeed punch above its weight but not without good reason and justification

Dave Scott of Tepnal Pharma Services discusses the success of the life sciences industry and how the Scotsman conference can contribute to this.  To date, 2018 has been another great year for our Life Sciences community. Across the spectrum of different  disciplines that make up Life Sciences in Scotland, both pure science and applied science companies continue to compete and win on a global platform. The...

DYSIS Medical Raises £18 Million to Accelerate Growth

DYSIS Medical Ltd, the developer of the innovative DYSIS Ultra colposcope used in cervical cancer screening, announces today the completion of an £18 million ($25 million) investment. Within the past year, DYSIS Medical has made significant strides and achieved key milestones including the launch of the latest generation device (DYSIS Ultra), the publication of updated guidance recommending the adoption of DYSIS by the NHS, and...

Omega Diagnostics sells infectious disease business for up to £2.18m

Interesting piece of industry news that explores Scottish life sciences firm Omega Diagnostics decision to begin a strategic divestment in order to realise value for shareholders in the short-term. The firm has struck a deal to sell most of its infectious disease business to a French buyer. The deal with Novacyt will see Alva-based Omega, which develops tests for allergies and food intolerance, receive up to...

AorTech to work on synthetic

Surrey-based medical device company AorTech has signed a development agreement with a Scottish business to work on its synthetic heart valve project. The project with VFT involves detailed computational modelling and analysis of AorTech’s heart valve, leading to further design optimisation, manufacturing and testing. The aim is to prepare a detailed data pack to justify first “in man” testing of the technology. Bill Brown, chairman...

Top